These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21459960)

  • 1. Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus.
    Giannitti C; Sebastiani GD; Manganelli S; Galeazzi M
    J Rheumatol; 2011 Apr; 38(4):780-1. PubMed ID: 21459960
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
    J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ; Kim JK; Park MC; Park YB; Lee SK
    J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature.
    Fotiadou C; Lazaridou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2011 Apr; 25(4):471-4. PubMed ID: 20561122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of rheumatic diseases in patients with HCV and HIV infection.
    Galeazzi M; Giannitti C; Manganelli S; Benucci M; Scarpato S; Bazzani C; Caporali R; Sebastiani GD
    Autoimmun Rev; 2008 Dec; 8(2):100-3. PubMed ID: 18694850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Mitroulis I; Hatzara C; Kandili A; Hadziyannis E; Vassilopoulos D
    Ann Rheum Dis; 2013 Feb; 72(2):308-10. PubMed ID: 22930597
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection.
    Nosotti L; Francesconi F; Izzi S; Berardesca E; Morrone A; Bonifati C
    Br J Dermatol; 2010 Jun; 162(6):1408-10. PubMed ID: 20184582
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
    Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
    Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases.
    Cheng J; Li JB; Sun QL; Li X
    J Rheumatol; 2011 Jan; 38(1):181-2. PubMed ID: 21196589
    [No Abstract]   [Full Text] [Related]  

  • 11. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.
    Wendling D; Auge B; Bettinger D; Lohse A; Le Huede G; Bresson-Hadni S; Toussirot E; Miguet JP; Herbein G; Di Martino V
    Ann Rheum Dis; 2005 May; 64(5):788-9. PubMed ID: 15834064
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases.
    Pereira R; Raposo I; Nery F; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):285-287. PubMed ID: 29054331
    [No Abstract]   [Full Text] [Related]  

  • 13. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases.
    Huvers FC; Popa C; Netea MG; van den Hoogen FH; Tack CJ
    Ann Rheum Dis; 2007 Apr; 66(4):558-9. PubMed ID: 17360784
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic viral hepatitis and TNF-alpha blockade.
    Raftery G; Griffiths B; Kay L; Kane D
    Rheumatology (Oxford); 2007 Aug; 46(8):1381; author reply 1381-2. PubMed ID: 17567635
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
    Haraoui B
    J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations.
    Fuchs I; Abu-Shakra M; Sikuler E
    Isr Med Assoc J; 2013 Jun; 15(6):303-7. PubMed ID: 23882898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 20. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
    Vassilopoulos D; Calabrese LH
    Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.